Disease, Drug Research and Therapies

Allogene taps Arbor in pursuit of ‘off-the-shelf’ CAR-T therapies for autoimmune disease

BioPharma Drive: Drug Pricing

MARCH 12, 2024

Allogene’s partnership with Arbor is designed to help the company stand out in what’s quickly become one of the industry’s hottest areas of drug research.

Therapies

Therapies Disease Drug Research Research

In vivo preclinical models for immune-mediated inflammatory disease drug development

Crown Bioscience

AUGUST 2, 2021

In this blog we will explore immune-mediated inflammatory diseases (IMIDs) —which represent a diverse group of conditions characterized by an excessive and/or inappropriate immune response.

Disease

Disease Drug Development Immune Response Drugs

An Evolving Regulatory Environment for Rare and Orphan Diseases

Advarra

AUGUST 16, 2022

A rare, or orphan, disease by definition affects a small percentage of the population — fewer than 200,000 people in the U.S. But the numbers add up, and taken together, rare diseases impact an estimated 30 million Americans. Since then, the FDA has significantly changed its approach to rare and orphan diseases.

Disease

Disease Clinical Trials FDA Approval FDA

AI in gene delivery vector discovery and design

Drug Target Review

OCTOBER 26, 2023

Genome engineering and gene therapies that manipulate DNA sequences in cells have driven a biotechnological revolution over the past decade. 1 Adeno-associated virus (AAV) vectors are the leading platform for in vivo gene delivery for the treatment of various human diseases. Molecular Therapy 20 , 1831-1832 (2012).

Engineering

Engineering Virus Therapies Immune Response

Unlocking Undruggable Targets: Shifting Paradigms in Modern Drug Discovery

DrugBank

MAY 15, 2024

Today, we're able to identify and target specific molecules involved in disease processes—a method that's much more like using a sniper rifle than throwing darts blindfolded. Among these targets are proteins, receptors, and enzymes that are fundamental to disease mechanisms.

Small Molecule

Small Molecule Molecular Biology Drugs Disease

eBook: Unlocking Undruggable Targets

DrugBank

AUGUST 20, 2024

The world of drug discovery is in a state of transformation, with advancements in biotechnology opening doors to new possibilities for targeting previously "undruggable" disease mechanisms. We also explore why some disease-associated targets remain elusive and how recent innovations are changing that narrative.

Therapies

Therapies Pharmaceuticals Disease Research

Deliberate Dysentery

Codon

JANUARY 21, 2024

Today, refined versions of these human challenge studies have become standard practice in testing vaccines for vector-borne diseases (e.g., yellow fever, malaria, and dengue), evaluating new drugs or treatments, and studying pathogenesis, the process by which a disease develops. Why are challenge trials becoming more popular?

Vaccine

Vaccine Trials Disease Treatment

World Malaria Day 2021

The Pharma Data

APRIL 24, 2021

The COVID-19 pandemic highlights the importance of robust health systems to respond to disease outbreaks and to control other deadly diseases such as malaria. In 2020, we discovered another novel malaria therapy, INE963, which has an entirely new mechanism of action and is expected to begin clinical trials in 2021.

Clinical Trials

Clinical Trials Treatment Trials Disease

Distinguishing the Roles of Preclinical vs. Clinical CROs in Clinical Research

Vial

MAY 20, 2024

In this article, we will define preclinical and clinical CROs, as well as highlight the unique needs and challenges of these organizations in their respective stages of drug research. What is a Pre-Clinical CRO? The global preclinical CRO market was estimated to be valued at US$5.7 billion in 2022 and is projected to reach US$10.2

Clinical Research

Clinical Research Clinical Trials Research Trials

ACTIV Update: Making Major Strides in COVID-19 Therapeutic Development

NIH Director's Blog: Drug Development

FEBRUARY 16, 2021

This improvement stems from several factors, including the FDA’s emergency use authorization (EUA) of a number of therapies found to be safe and effective for COVID-19. ACTIV was founded last April to accelerate drug research that typically requires more than a decade of clinical ups and downs to develop a safe, effective therapy.

Clinical Trials

Clinical Trials Trials Hospitals Vaccine

New Data Show Treatment with Lilly’s Neutralizing Antibodies Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) Together Reduced Risk of COVID-19 Hospitalizations and Death by 70 Percent

The Pharma Data

JANUARY 26, 2021

percent) in patients taking therapy and 36 events (7.0 Bamlanivimab and etesevimab together also demonstrated statistically significant improvements on all key secondary endpoints, providing strong evidence that the therapy reduced viral load and accelerated symptom resolution. who require oxygen therapy due to COVID-19, OR.

Hospitals

Hospitals Treatment Trials Long-Term Care Facilities

Article EMA Thank You What will the orphan drug market exclusivity haircut mean for industry?

Agency IQ

JUNE 9, 2023

The problems: Although the current regulation stimulated orphan drug research, it didn’t do enough The regulation fostered development of medicines for rare diseases since implementation, but not enough. However, 95% of the over 6,000 recognized orphan diseases still have no treatment options.

Marketing

Marketing Regulations Biosimilars Drugs

Origins of the Lab Mouse

Codon

JUNE 2, 2024

Without mouse models, we may never have developed polio and meningitis vaccines, organ transplants, GLP-1 drugs, gene therapies , or any other number of transformative treatments. Today, somewhere on the order of 30 million rodents are used yearly in biomedical research in the U.S. In a testimony in front of the U.S.

Laboratories

Laboratories Research Disease Science

Using clinical genomics and AI in drug development to elevate success

Drug Target Review

FEBRUARY 11, 2025

Biologics have gone from monoclonal antibodies to complex bi- and tri-specific antibodies, as well as antibody-drug conjugates. Cell and gene therapies offer patients the possibility of living a relatively normal lifetime, with potential cures for deadly diseases.

Drug Development

Drug Development Bioinformatics Drugs Small Molecule

Drug Discovery Digest